Clinical Implications of the Genetic Background in Pediatric Pulmonary Arterial Hypertension: Data from the Spanish REHIPED Registry

Background: Pulmonary arterial hypertension (PAH) is a severe and rare disease with an important genetic background. The influence of genetic testing in the clinical classification of pediatric PAH is not well known and genetics could influence management and prognosis.

Objectives: The aim of this work was to identify the molecular fingerprint of PH children in the (REHIPED), and to investigate if genetics could have an impact in clinical reclassification and prognosis.

Methods: We included pediatric patients with a genetic analysis from REHIPED. From 2011 onward, successive genetic techniques have been carried out. Before genetic diagnosis, patients were classified according to their clinical and hemodynamic data in five groups. After genetic analysis, the patients were reclassified. The impact of genetics in survival free of lung transplantation was estimated by Kaplan-Meier curves.

Results: Ninety-eight patients were included for the analysis. Before the genetic diagnoses, there were idiopathic PAH forms in 53.1%, PAH associated with congenital heart disease in 30.6%, pulmonary veno-occlusive disease-PVOD-in 6.1%, familial PAH in 5.1%, and associated forms with multisystemic disorders-MSD-in 5.1% of the patients. Pathogenic or likely pathogenic variants were found in 44 patients (44.9%). After a genetic analysis, 28.6% of the cohort was "reclassified", with the groups of heritable PAH, heritable PVOD, TBX4, and MSD increasing up to 18.4%, 8.2%, 4.1%, and 12.2%, respectively. The MSD forms had the worst survival rates, followed by PVOD.

Conclusions: Genetic testing changed the clinical classification of a significant proportion of patients. This reclassification showed relevant prognostic implications.

Citing Articles

Pulmonary Hypertension: Molecular Mechanisms and Clinical Studies.

Adu-Amankwaah J, You Q, Liu X, Jiang J, Yang D, Liu K MedComm (2020). 2025; 6(3):e70134.

PMID: 40066229 PMC: 11892029. DOI: 10.1002/mco2.70134.

Pulmonary arterial hypertension related to congenital heart disease with a left-to-right shunt: phenotypic spectrum and approach to management.

Ferrero P, Constantine A, Chessa M, Dimopoulos K Front Cardiovasc Med. 2024; 11:1360555.

PMID: 38784170 PMC: 11111857. DOI: 10.3389/fcvm.2024.1360555.

Pulmonary Hypertension and Hypothyroidism-Still an Important Clinical Coincidence in Paediatric Population, an Endocrinologist's Point of View.

Lecka-Ambroziak A, Kot K Life (Basel). 2024; 14(3).

PMID: 38541628 PMC: 10971378. DOI: 10.3390/life14030302.

Genes in pediatric pulmonary arterial hypertension and the most promising gene therapy.

Dai L, Du L Front Genet. 2022; 13:961848.

PMID: 36506323 PMC: 9730536. DOI: 10.3389/fgene.2022.961848.

References

Tenorio J, Navas P, Barrios E, Fernandez L, Nevado J, Quezada C . A founder EIF2AK4 mutation causes an aggressive form of pulmonary arterial hypertension in Iberian Gypsies. Clin Genet. 2014; 88(6):579-83. DOI: 10.1111/cge.12549. View

Li H, Xie W, Huang X, Lu X, Zhai Z, Zhan Q . Pulmonary Hypertension in Glycogen Storage Disease Type II. Chin Med J (Engl). 2018; 131(11):1375-1376. PMC: 5987515. DOI: 10.4103/0366-6999.232792. View

Montani D, Lechartier B, Girerd B, Eyries M, Ghigna M, Savale L . An emerging phenotype of pulmonary arterial hypertension patients carrying variants. Eur Respir J. 2022; 60(6). PMC: 10436756. DOI: 10.1183/13993003.00656-2022. View

Levy M, Eyries M, Szezepanski I, Ladouceur M, Nadaud S, Bonnet D . Genetic analyses in a cohort of children with pulmonary hypertension. Eur Respir J. 2016; 48(4):1118-1126. DOI: 10.1183/13993003.00211-2016. View

Roberts K, McElroy J, Wong W, Yen E, Widlitz A, Barst R . BMPR2 mutations in pulmonary arterial hypertension with congenital heart disease. Eur Respir J. 2004; 24(3):371-4. DOI: 10.1183/09031936.04.00018604. View

Chida A, Shintani M, Yagi H, Fujiwara M, Kojima Y, Sato H . Outcomes of childhood pulmonary arterial hypertension in BMPR2 and ALK1 mutation carriers. Am J Cardiol. 2012; 110(4):586-93. DOI: 10.1016/j.amjcard.2012.04.035. View

Komhoff M, Roofthooft M, Westra D, Teertstra T, Losito A, van de Kar N . Combined pulmonary hypertension and renal thrombotic microangiopathy in cobalamin C deficiency. Pediatrics. 2013; 132(2):e540-4. DOI: 10.1542/peds.2012-2581. View

Tenorio Castano J, Hernandez-Gonzalez I, Gallego N, Perez-Olivares C, Ochoa Parra N, Arias P . Customized Massive Parallel Sequencing Panel for Diagnosis of Pulmonary Arterial Hypertension. Genes (Basel). 2020; 11(10). PMC: 7650688. DOI: 10.3390/genes11101158. View

van Gent M, Velthuis S, Post M, Snijder R, Westermann C, Letteboer T . Hereditary hemorrhagic telangiectasia: how accurate are the clinical criteria?. Am J Med Genet A. 2013; 161A(3):461-6. DOI: 10.1002/ajmg.a.35715. View

10.

van Loon R, Roofthooft M, van Osch-Gevers M, Delhaas T, Strengers J, Blom N . Clinical characterization of pediatric pulmonary hypertension: complex presentation and diagnosis. J Pediatr. 2009; 155(2):176-82.e1. DOI: 10.1016/j.jpeds.2009.02.036. View

11.

Humbert M, McLaughlin V, Gibbs J, Gomberg-Maitland M, Hoeper M, Preston I . Sotatercept for the Treatment of Pulmonary Arterial Hypertension. N Engl J Med. 2021; 384(13):1204-1215. DOI: 10.1056/NEJMoa2024277. View

12.

Navarro-Sastre A, Tort F, Stehling O, Uzarska M, Arranz J, Del Toro M . A fatal mitochondrial disease is associated with defective NFU1 function in the maturation of a subset of mitochondrial Fe-S proteins. Am J Hum Genet. 2011; 89(5):656-67. PMC: 3213398. DOI: 10.1016/j.ajhg.2011.10.005. View

13.

Bourque D, Fonseca I, Staines A, Teitelbaum R, Axford M, Jobling R . Alveolar capillary dysplasia with misalignment of the pulmonary veins and hypoplastic left heart sequence caused by an in frame deletion within FOXF1. Am J Med Genet A. 2019; 179(7):1325-1329. DOI: 10.1002/ajmg.a.61162. View

14.

Suso J, Del Cerro Marin M, Dorao Martinez-Romillo P, Labrandero de Lera C, Garcia-Moya L, Rodriguez Gonzalez J . Nonketotic hyperglycinemia presenting as pulmonary hypertensive vascular disease and fatal pulmonary edema in response to pulmonary vasodilator therapy. J Pediatr. 2012; 161(3):557-9. DOI: 10.1016/j.jpeds.2012.04.044. View

15.

Zhu N, Gonzaga-Jauregui C, Welch C, Ma L, Qi H, King A . Exome Sequencing in Children With Pulmonary Arterial Hypertension Demonstrates Differences Compared With Adults. Circ Genom Precis Med. 2018; 11(4):e001887. PMC: 5896781. DOI: 10.1161/CIRCGEN.117.001887. View

16.

Benza R, Miller D, Barst R, Badesch D, Frost A, McGoon M . An evaluation of long-term survival from time of diagnosis in pulmonary arterial hypertension from the REVEAL Registry. Chest. 2012; 142(2):448-456. DOI: 10.1378/chest.11-1460. View

17.

De Felice C, Guazzi G, Rossi M, Ciccoli L, Signorini C, Leoncini S . Unrecognized lung disease in classic Rett syndrome: a physiologic and high-resolution CT imaging study. Chest. 2010; 138(2):386-92. DOI: 10.1378/chest.09-3021. View

18.

Del Cerro M, Abman S, Diaz G, Freudenthal A, Freudenthal F, Harikrishnan S . A consensus approach to the classification of pediatric pulmonary hypertensive vascular disease: Report from the PVRI Pediatric Taskforce, Panama 2011. Pulm Circ. 2011; 1(2):286-298. PMC: 3161725. DOI: 10.4103/2045-8932.83456. View

19.

Chomette L, Migeotte I, Dewachter C, Vachiery J, Smits G, Bondue A . Early-onset and severe pulmonary arterial hypertension due to a novel compound heterozygous association of rare mutations: A case report and review of existing data. Pulm Circ. 2022; 12(2):e12052. PMC: 9190294. DOI: 10.1002/pul2.12052. View

20.

Pienkos S, Gallego N, Condon D, Cruz-Utrilla A, Ochoa N, Nevado J . Novel and Variants Are Implicated in the Pathogenesis of Pulmonary Arterial Hypertension. Front Med (Lausanne). 2021; 8:625763. PMC: 8119639. DOI: 10.3389/fmed.2021.625763. View